Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects

The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus CV Risk Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition
Have signed informed consent

Exclusion criteria

Patients with ALT > 2.5x the normal value
With heart failure symptoms
With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates
With recent myocardial infarction (<6 months)
With severe renal disfunction
Pregnant or lactating or planned to be pregnant during the study
Under investigational drug treatment
Alcoholic or drug abuser

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece

Important dates

Study start: 2004
First posted: Apr 1, 2008
Registry last updated: Oct 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed